NCT04659122View on ClinicalTrials.gov

A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 17, 2021

Primary Completion Date

February 23, 2023

Study Completion Date

February 23, 2023

Conditions
COVID-19Undefined
Interventions
BIOLOGICAL

AT-100

reconstituted AT-100 for intratracheal administration

Trial Locations (1)

45229

Airway Therapeutics Investigational Site, Cincinnati

Sponsors
All Listed Sponsors
lead

Airway Therapeutics, Inc.

INDUSTRY

NCT04659122 - A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia | Biotech Hunter | Biotech Hunter